[go: up one dir, main page]

MX9710003A - Composiciones androgenicas dirigidas. - Google Patents

Composiciones androgenicas dirigidas.

Info

Publication number
MX9710003A
MX9710003A MX9710003A MX9710003A MX9710003A MX 9710003 A MX9710003 A MX 9710003A MX 9710003 A MX9710003 A MX 9710003A MX 9710003 A MX9710003 A MX 9710003A MX 9710003 A MX9710003 A MX 9710003A
Authority
MX
Mexico
Prior art keywords
androgenic
cells
cytostatic
androgenic receptors
receptors
Prior art date
Application number
MX9710003A
Other languages
English (en)
Other versions
MXPA97010003A (es
Inventor
Milos Sovak
Jerome C Bressi
James Gordon Douglass Iii
Brian Campion
Wolfgang Wrasidlo
Original Assignee
Biphysica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biphysica Inc filed Critical Biphysica Inc
Publication of MX9710003A publication Critical patent/MX9710003A/es
Publication of MXPA97010003A publication Critical patent/MXPA97010003A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan feniltiohidantoínas sustituidas utiles para detectar la presencia de células tumorales que tienen receptores androgénicos y que proporacionan actividad citostática y citotoxica para tales células. Los compuestos objeto proporacionan vehículos para el blanco específico al receptor androgénico que contiene células de agentes citostátiacos y/o citotoxicos, átomos raiocativos o radioopacos pesados o ligeros y similares para la deteccion y tratamiento de las células cancerosas que involucran receptores androgénicos o bloquear receptores androgénicos.
MXPA/A/1997/010003A 1995-06-16 1997-12-10 Composiciones androgenicas dirigidas MXPA97010003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/491,130 US5656651A (en) 1995-06-16 1995-06-16 Androgenic directed compositions
US08491130 1995-06-16

Publications (2)

Publication Number Publication Date
MX9710003A true MX9710003A (es) 1998-08-30
MXPA97010003A MXPA97010003A (es) 1998-11-12

Family

ID=

Also Published As

Publication number Publication date
EP0854716A4 (en) 1999-04-07
EP0854716A1 (en) 1998-07-29
AU712609B2 (en) 1999-11-11
JPH10510845A (ja) 1998-10-20
CA2225484A1 (en) 1997-01-03
WO1997000071A1 (en) 1997-01-03
KR19990028276A (ko) 1999-04-15
AU6332996A (en) 1997-01-15
US5656651A (en) 1997-08-12

Similar Documents

Publication Publication Date Title
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
AU3216893A (en) Methods for admininstration of taxol
IL99906A0 (en) Quinazoline derivatives for enhancing antitumor activity
NZ308789A (en) Tetralin derivatives and medicaments
AU5835098A (en) Use of pyrimidine derivatives for the prevention of cancer, on their own or in combination with other therapeutic measures
BR9709942A (pt) Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
FI973118A0 (fi) Lymfotoksiini-alfa/beta-komplekseja ja antilymfotoksiini-beta-reseptorivasta-aineita kasvaimenvastaisina aineina
NZ237688A (en) Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
TR199800244T2 (xx) Griseofulvinin, kanserlerin ilerlemesini �nlemede kullan�m�.
NO980419L (no) Anvendelse av 1H,2,4-triazol derivater for å inhibere cancervekst
CA2081343A1 (fr) Agents therapeutiques pour le traitement de la resistance multi-drogue dans les cas de cancer
IL97055A0 (en) Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives
MX9606559A (es) Terapia para el cancer usando linfotoxina.
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
MX9710003A (es) Composiciones androgenicas dirigidas.
ZA986720B (en) Photoresponsive sunscreen compositions
WO2002042318A3 (en) Transcobalamin receptor binding conjugates for neutron capture therapy
JO2199B1 (en) Replaced pyrrols
AU3274597A (en) Remedies and preventives for stomatitis
HU9601498D0 (en) Use of dimeticone for treating constipation
EP0778833A4 (en) ENDOTHELIN RECEPTOR ANTAGONISTS
AU1956399A (en) Composition containing propargylamine for enhancing cancer therapy
TR200103405T2 (tr) İkiişlevli antikorlar ve bunların tümör-önleyici amilleri hedeflemede kullanımı.
Uadia et al. Hydrolysis of methotrexate-immunoglobulin conjugates by liver homogenates and characterization of catabolites